The estimated Net Worth of James J O'leary is at least $1.29 Million dollars as of 11 July 2013. Dr leary owns over 35,000 units of Fusion Pharmaceuticals stock worth over $754,250 and over the last 16 years he sold FUSN stock worth over $0. In addition, he makes $537,640 as Chief Medical Officer at Fusion Pharmaceuticals.
Dr has made over 5 trades of the Fusion Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 35,000 units of FUSN stock worth $144,200 on 11 July 2013.
The largest trade he's ever made was exercising 35,000 units of Fusion Pharmaceuticals stock on 11 July 2013 worth over $144,200. On average, Dr trades about 7,333 units every 8 days since 2008. As of 11 July 2013 he still owns at least 35,000 units of Fusion Pharmaceuticals stock.
You can see the complete history of Dr leary stock trades at the bottom of the page.
Dr. James J. O'Leary is the Chief Medical Officer at Fusion Pharmaceuticals.
As the Chief Medical Officer of Fusion Pharmaceuticals, the total compensation of Dr Leary at Fusion Pharmaceuticals is $537,640. There are 3 executives at Fusion Pharmaceuticals getting paid more, with Dr. John F. Valliant having the highest compensation of $845,495.
Dr Leary is 56, he's been the Chief Medical Officer of Fusion Pharmaceuticals since . There are no older and 6 younger executives at Fusion Pharmaceuticals.
James's mailing address filed with the SEC is C/O FUSION PHARMACEUTICALS, INC., 2 INTERNATIONAL PLACE, SUITE 2310, BOSTON, MA, 02110.
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams und & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include: